Istradefylline: First Global Approval

Kyowa Hakko Kirin is developing istradefylline, a selective adenosine A 2A receptor antagonist, for the once-daily oral treatment of Parkinson’s disease (PD). Adenosine A 2A receptors are considered to be present particularly in the basal ganglia of the brain; the degeneration or abnormality observe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2013-06, Vol.73 (8), p.875-882
Hauptverfasser:	Dungo, Rosselle, Deeks, Emma D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Adenosine A2 Receptor Antagonists - pharmacokinetics Adenosine A2 Receptor Antagonists - pharmacology Agreements Anticonvulsants. Antiepileptics. Antiparkinson agents Basal Ganglia - drug effects Basal Ganglia - metabolism Biological and medical sciences Brain Dopamine Dopamine - metabolism Drug Approval Drug dosages Dyskinesia Humans Internal Medicine Japan Medical sciences Medicine Medicine & Public Health Neuropharmacology Oral administration Parkinson Disease - drug therapy Parkinson Disease - metabolism Parkinson's disease Pharmaceuticals Pharmacokinetics Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Purines - pharmacokinetics Purines - pharmacology R & D Insight Report
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!